NSI189
CAS: 1270138-40-3
MF: C22H30N4O
EINECS No. : 1592732-453-0
MF: C22H30N4O
EINECS No. : 1592732-453-0
API368
Quantity
NSI189 is an investigational drug being developed by Neuralstem Inc., a biopharmaceutical company.
NSI189 is a small molecule in clinical development for major depressive disorder (MDD)
and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment,
Type 1 and Type 2 diabetes, and stroke.
NSI189 was studied in phase I and II clinical trials for the treatment of major depressive disorder.
NSI189 is an experimental, potential antidepressant, for the treatment for major depressive disorder (MDD),
as well as for cognitive impairment and neurodegeneration.
